← Dashboard

Compliance Alert: Wegovy Pill

Configure Methodology
72
Caution

Wegovy Pill scores 72/100 (Caution) based on analysis of 75s promotional content. 2 enforcement patterns detected across Visual Distraction, Efficacy — “Family & Social Scenes” identified at 40.1s, previously cited in Jardiance (x3), Contrave, Qulipta. FDA enforcement letter on file dated Feb 5, 2026. Weakest dimension: Efficacy at 61/100.

Wegovy Pill | Novo Nordisk | DTC Broadcast
FDA Letter Mar 7, 2026

Patterns Detected (2)

Matched against 14 enforcement patterns from 42 FDA letters

Visual Distraction
Family & Social Scenes
Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals
73
40.1s – 46.1s
46.2s – 54.1s
FDA Precedent: Jardiance (x3), Contrave, Qulipta, Calquence, Austedo (x2) 21 CFR 202.1(e)(1)
Efficacy
Dramatic Before/After
Advertisements cannot be false or misleading in any particular
61
FDA Precedent: TURALIO, TREMFYA 21 CFR 202.1(e)(5)
72
Master
73
Visual
30%
61
Efficacy
25%
78
Fair Balance
20%
83
Adeq Prov
15%
--
Lifecycle
10%
Safety Information Window
Risk disclosure: 24.8s – 66.0s (41.2s of 75.2s total — 54.7% of ad)
40.1s — Family Social
46.2s — Family Social
0s75s
!
FDA Enforcement Action on File
FDA Letter Feb 5, 2026 View PDF →

Visual Evidence (2 clips)

40.1s – 46.1s Family Social
46.2s – 54.1s Family Social

Recommendations

high
Initiate PromoMats review: Verify all efficacy claims against current approved labeling. Visual representations should align with clinical trial results referenced in the PI.
high
Escalate to regulatory affairs: FDA enforcement letter on file (Feb 5, 2026). Verify remediation status in PromoMats and confirm all content modifications address cited violations before next distribution.

Powered by cQuenced